[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524716":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":47,"responsibleParty":80,"collaborators":83,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":42,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":42,"enrollmentInfo":96,"targetDuration":42,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":50,"whyStopped":42,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University of California, Irvine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Neostigmine plus Glycopyrrolate","ACTIVE_COMPARATOR","0.07 mg\u002Fkg Neostigmine plus 0.014 mg\u002Fkg glycopyrrolate\n\n2 syringes numbered 1 and 2\n\n1. Syringe #1: Glycopyrrolate\n2. Syringe #2: Neostigmine",[13],"Drug: Neostigmine Injectable Solution",{"label":15,"type":10,"description":16,"interventionNames":17},"Sugammadex","2.0 mg\u002Fkg of Sugammadex plus saline equivalent\n\n2 syringes numbered 1 and 2\n\n1. Syringe #1: 0.9% sodium chloride\n2. Syringe #2: : full Sugammadex dose + 0.9 sodium chloride (QS to match volume)",[18],"Drug: Sugammadex injection",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Neostigmine Injectable Solution","Examine GI-2 recovery",[9],[9,26],"Group B",{"type":21,"name":28,"description":23,"armGroupLabels":29,"otherNames":30},"Sugammadex injection",[15],[15,31],"Group A",[33],{"name":34,"affiliation":35,"role":36},"Robert R Field, MD","Associate Clinical Professor","PRINCIPAL_INVESTIGATOR",[38,44],{"name":39,"role":40,"phone":41,"phoneExt":42,"email":43},"David Whaley","CONTACT","714-456-5501",null,"whaleyd@hs.uci.edu",{"name":34,"role":40,"phone":45,"phoneExt":42,"email":46},"714-506-5703","fieldr@hs.uci.edu",[48],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"UC Irvine Medical Center","RECRUITING","Orange","California","92868","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.85311,33.78779,{"lat":60,"lon":59},[63,66,67,70,72,74,76,78],{"name":64,"role":40,"phone":65,"phoneExt":42,"email":43},"David Whaley, MS","714.456.5501",{"name":34,"role":36,"phone":42,"phoneExt":42,"email":42},{"name":68,"role":69,"phone":42,"phoneExt":42,"email":42},"Joseph C Carmichael, MD","SUB_INVESTIGATOR",{"name":71,"role":69,"phone":42,"phoneExt":42,"email":42},"Steven D Mills, MD",{"name":73,"role":69,"phone":42,"phoneExt":42,"email":42},"Skandan Shanmugan, MD",{"name":75,"role":69,"phone":42,"phoneExt":42,"email":42},"Valery C ilchez, MD",{"name":77,"role":69,"phone":42,"phoneExt":42,"email":42},"Matthew D Whealon, MD",{"name":79,"role":69,"phone":42,"phoneExt":42,"email":42},"Paulette Mensah, BA",{"type":36,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Robert Ryan Field","Associate Clinical Professor, Dept of Anesthesiology & Perioperative Medicine",[84],{"name":85,"class":86},"Merck Sharp & Dohme LLC","INDUSTRY","100524716","phase-4-neuromuscular-blockade-comparison-for-gi-2-recovery-after-bowel-resection-100524716",false,"NCT06112353","Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection","Sugammadex VS Neostigmine and Glycopyrrolate Reversal of Neuromuscular Relaxation For Time to Return of Bowel Function After Bowel Resection: Prospective, Randomized, Triple-blinded Clinical Trial For Quality Improvement","Inclusion Criteria:\n\n* Age 18 or older\n* Laparoscopic bowel resection surgery under general anesthesia with nondepolarizing neuromuscular blockade with rocuronium or vecuronium, and requiring inpatient admission\n\nExclusion Criteria:\n\n* Allergy to Rocuronium, Vecuronium, or Sugammadex\n* Bowel resection surgery requiring an ostomy\n* No severe valvulopathy, no systolic heart failure with reduced ejection fraction (HFrEF), no coronary artery disease with positive stress test for ischemic regional wall motion abnormality\n* No autoimmune pulmonary disease, no severe pulmonary fibrosis, no severe pulmonary hypertension, no COPD with requirement of home oxygen, no pulmonary cancer of primary or metastatic origin\n* Creatinine Clearance (CrCl) of less than 30\n* Pregnancy\n* Incapable of providing consent or understanding the research project","ALL","18 Years",{"count":97,"type":98},128,"ESTIMATED","INTERVENTIONAL",[101],"PHASE4","The purpose of this research study is to see the outcome of Sugammadex versus Neostigmine with Glycopyrrolate in colorectal surgery as it relates to its effects on post-surgical time (in hours) to first bowel movement and tolerance for solid food (GI-2 recovery) following bowel resection surgery",[104],"Intestinal Disease",[106,15,107,108,109],"Laparoscopic Bowel Resection","Neostigmine","Glycopyrrolate","GI-2","2026-01-21",{"date":112,"type":113},"2026-01-23","ACTUAL",{"date":115,"type":113},"2024-04-17",{"date":117,"type":98},"2026-07-31",{"name":5,"class":6},1]